Stephanie Page, DO
Obesity Medicine · Morehead City, NCNPI 1265842900
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Novo Nordisk at 50.6% of the total. 2025 is the largest year on record at $61,243, more than ten times the $152 reported in 2019.
Across 164 payments — averaging $393.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$33K
- Corcept Therapeutics$18K
- Eli Lilly$12K
- Amgen$408
- Bayer$253
- Medtronic$234
- plus $1K from 17 others
What the payments were for
- Consulting fees$3,8706%
- Speaking & faculty fees$36,11456%
- Travel & lodging$10,59316%
- Food & beverage$13,87522%
- Education$390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 43 | $32,633 |
| Corcept Therapeutics | 33 | $18,351 |
| Eli Lilly | 14 | $11,543 |
| Amgen | 15 | $408 |
| Bayer | 13 | $253 |
| Medtronic(2 entities) | 4 | $234 |
| Insulet Corporation | 4 | $218 |
| Abbott | 6 | $127 |
| Currax Pharmaceuticals LLC | 2 | $108 |
| Lilly USA, LLC | 7 | $106 |
| Madrigal Pharmaceuticals | 3 | $90 |
| Sequel Med Tech, LLC | 3 | $81 |
| Boehringer Ingelheim | 3 | $56 |
| Rhythm Pharmaceuticals, Inc. | 2 | $54 |
| Sanofi-aventis U.S. LLC | 2 | $48 |
| Phathom Pharmaceuticals, Inc. | 2 | $40 |
| Cequr Corporation | 2 | $28 |
| Tandem Diabetes Care, Inc. | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Pfizer | 1 | $18 |
| Ascensia Diabetes Care US Inc. | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| AstraZeneca | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few obesity medicine providers in North Carolinato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 212 | $257,163 |
| MounjaroTirzepatide | 122 | $140,714 |
| JardianceEmpagliflozin | 49 | $45,614 |
| RybelsusSemaglutide | 15 | $29,910 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $19,151 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 14 | $16,148 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $13,044 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $9,232 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 24 | $8,534 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $6,336 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $5,977 |
| Novolog FlexpenInsulin Aspart | 25 | $5,153 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 23 | $2,624 |
| Metformin Hcl ErMetformin Hcl | 105 | $972 |
| Ultra-Fine Nano Pen NeedlePen Needle, Diabetic | 11 | $847 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $32,633 | $287,073227 claims |
| Lilly USA, LLCMounjaro | $106 | $140,714122 claims |
| Boehringer IngelheimJardiance | $56 | $45,61449 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $16 | $26019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few obesity medicine providers in North Carolinaon file to place this against a meaningful peer group, so we don't.
Other obesity medicine in Morehead City
- Tiffany Lowe ClaytonFuquay Varina$455K
- Melody CovingtonCharlotte$100K
- Sriram MachineniChapel Hill$57K
- Kristina LewisWinston Salem$14K
- Rebecca ManganelloCary$2K
- Thomas MarloweCharlotte$984
- Alex TseCary$770
- Karen BowenKernersville$699
- Alexandra GieddCharlotte$653
- Julie HowsonWaxhaw$557
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.